Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight

Phase 3

Active, not recruiting

Conditions: Obesity or Overweight

Interventions: Drug: Cagrilintide
Drug: Semaglutide
Drug: Placebo Semaglutide
Drug: Placebo Cagrilintide

First Posted Date: 2023-08-18

Last Posted Date: 2024-11-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 300

Registration Number: NCT05996848

Locations: 🇨🇳
Suzhou Municipal Hospital, Suzhou, Jiangsu, China
🇨🇳
Tongren Hospital Shanghai Jiao Tong Univ. School of Medicine, Shanghai, Shanghai, China
🇨🇳
Chinese People's Liberation Army General Hospital, Beijing, Beijing, China

and more 22 locations

A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood

Phase 1

Recruiting

Conditions: Dyslipidaemia
Healthy Volunteers

Interventions: Drug: NNC0491-6075
Drug: Placebo

First Posted Date: 2023-08-07

Last Posted Date: 2023-08-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 106

Registration Number: NCT05979428

Locations: 🇺🇸
Novo Nordisk Investigational Site, Cypress, California, United States

A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function

Phase 1

Recruiting

Conditions: Healthy Volunteers
Hepatic Impairment

Interventions: Drug: NNC0194-0499

First Posted Date: 2023-06-26

Last Posted Date: 2024-08-22

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 35

Registration Number: NCT05917938

Locations: 🇵🇱
Uniwersyteckie Centrum Kliniczne (UCK), Gdańsk, Poland
🇸🇰
Summit Clinical Research s.r.o., Malacky, Slovakia
🇩🇪
APEX Research, München, Germany

A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature

Recruiting

Conditions: Idiopathic Short Stature

Interventions: Other: No treatment is given

First Posted Date: 2023-06-08

Last Posted Date: 2024-10-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 700

Registration Number: NCT05894876

Locations: 🇧🇷
University of Sao Paulo School of Medicine, São Pauloa, Brazil
🇺🇸
Novo Nordisk Investigational Site, Columbia, Maryland, United States

A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease

Phase 3

Active, not recruiting

Conditions: Alzheimers Disease

Interventions: Drug: Semaglutide
Drug: Placebo

First Posted Date: 2023-06-07

Last Posted Date: 2024-08-22

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT05891496

Locations: 🇮🇹
Fondazione Santa Lucia IRCCS, Roma, Italy
🇨🇦
Memory Program, Toronto, Ontario, Canada
🇸🇪
Karolinska Universitetssjukhuset, Huddinge, Stockholm, Sweden

and more 7 locations

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)

Phase 3

Active, not recruiting

Conditions: Overweight
Obesity

Interventions: Drug: Semaglutide Placebo
Drug: Semaglutide

First Posted Date: 2023-06-06

Last Posted Date: 2024-12-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 230

Registration Number: NCT05890976

Locations: 🇨🇳
Peking University People's Hospital-Endocrinology, Beijing, Beijing, China
🇨🇳
Beijing Friendship Hospital, Capital Medical University-Endocrinology, Beijing, Beijing, China
🇨🇳
Huizhou Central People's Hospital-Endocrinology, Huizhou, Guangdong, China

and more 12 locations

A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)

Phase 3

Completed

Conditions: Haemophilia A
Haemophilia A With Inhibitors

Interventions: Drug: NNC0365-3769 (Mim8) PPX

First Posted Date: 2023-05-30

Last Posted Date: 2024-11-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 61

Registration Number: NCT05878938

Locations: 🇩🇪
Vivantes Klinikum am Friedrichshain - Innere Medizin - Angiologie und Hämostaseologie, Berlin, Germany
🇩🇪
Universitätsklinikum Bonn - Institut für Experimentelle Hämatologie, Bonn, Germany
🇺🇸
Children's Hospital Los Angeles - Endocrinology, Los Angeles, California, United States

and more 25 locations

A Study to Characterize the Prevalence of Overweight and Obesity Among Patients With Established Cardiovascular Disease

Completed

Conditions: Overweight
Obesity

Interventions: Other: No treatment given

First Posted Date: 2023-05-24

Last Posted Date: 2024-07-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 5360

Registration Number: NCT05873660

Locations: 🇪🇸
Novo Nordisk Investigational Site, Madrid, Spain

A Research Study of a New Medicine NNC0519-0130 in Japanese and Non-Japanese Men

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: NNC0519-0130
Drug: Placebo

First Posted Date: 2023-05-23

Last Posted Date: 2024-05-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 22

Registration Number: NCT05870670

Locations: 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Japan

A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy

Conditions: Pregnancy
Obesity
Overweight

Interventions: Other: No Intervention

First Posted Date: 2023-05-23

Last Posted Date: 2023-10-06

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 728

Registration Number: NCT05872022

Locations: 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy